Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Disclosed herein are methods of cellular reprogramming, comprising contacting a cell with HC-HA/PTX3 for a time sufficient for cellular reprogramming of the phenotype of the cell to a different phenotype.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.

Described herein are methods for treating and preventing cancer. In particular, described herein are methods using SA-4-1BBL as a monotherapy agent to treat, prevent or reduce the risk of cancer, treat, prevent, or reduce the risk of tumorigenesis, and treat, prevent, or reduce the risk of post-surgical tumor recurrence. SA-4-1BBL for use as a monotherapy in such methods also is provided.

The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula TABLE-US-00001 X.sub.1X.sub.2X.sub.3X.sub.4X.sub.5GVX.sub.6AKAGVX.sub.7NX.sub.8FKSESY (SEQ ID NO: 1) (I) (X.sub.9).sub.nGVX.sub.10AKAGVX.sub.11NX.sub.12FKSESY (SEQ ID NO: 2) (II) YKX.sub.13LRRX.sub.14APRWDX.sub.15PLRDPALRX.sub.16X.sub.17L (SEQ ID NO: 3) (III) YKX.sub.18LRR(X.sub.19).sub.nPLRDPALRX.sub.20X.sub.21L (SEQ ID NO: 4) (IV) IKLSGGVQAKAGVINMDKSESM (SEQ ID NO: 5) (V) IKLSGGVQAKAGVINMFKSESY (SEQ ID NO: 6) (VI) IKLSGGVQAKAGVINMFKSESYK (SEQ ID NO: 7) (VII) GVQAKAGVINMFKSESY (SEQ ID NO: 8) (VIII) GVRAKAGVRNMFKSESY (SEQ ID NO: 9) (IX) GVRAKAGVRN(Nle)FKSESY (SEQ ID NO: 10) (X) YKSLRRKAPRWDAPLRDPALRQLL (SEQ ID NO: 11) (XI) YKSLRRKAPRWDAYLRDPALRQLL (SEQ ID NO: 12) (XII) YKSLRRKAPRWDAYLRDPALRPLL (SEQ ID NO: 13) (XIII) wherein X.sub.1 to X.sub.21 and n can have various different values and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end.

The present disclosure provides pharmaceutical compositions for treating fungal and bacterial infections. The pharmaceutical compositions of the disclosure comprise a cationic surfactant, a chelating agent, and at least one solvent. The pharmaceutical compositions of the disclosure can be used to treat drug-sensitive or multi drug-resistant bacterial or fungal infections.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle atrophy or myotonic dystrophy.